Results 61 to 70 of about 1,846,702 (390)

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies [PDF]

, 2013
Hepatitis C virus (HCV) infection is a major cause of liver disease and hepatocellular carcinoma. Glycan shielding has been proposed to be a mechanism by which HCV masks broadly neutralizing epitopes on its viral glycoproteins.
Adams, Alex Brown, Angus, Arvind H. Patel, Bartenschlager, Benedicto, Blight, Bradley, Broering, Bukh, Charles Eigenbrot, David Arnott, David J. Matthews, Dhillon, Diao, Emsley, Evans, Falkowska, Flint, Friebe, Gadgil, Gal-Tanamy, Giang, Goffard, Gordon, Helle, Helle, Herweijer, Homer Pantua, Hotzel, Iacob, Jingyu Diao, Jo-Anne Hongo, Kapadia, Kapadia, Kentaro Takeda, Kong, Kong, Krista McCutcheon, Lindenbach, Liu, Livak, Mark Ultsch, Mary Mathieu, McCaffrey, McCoy, Meredith Hazen, Moore, Murshudov, North, Otwinowski, Owsianka, Owsianka, Owsianka, Owsianka, Paborsky, Perotti, Phil Hass, Pikora, Pileri, Ploss, Potter, Qui Phung, Reed, Reesink, Robert F. Kelley, Sainz, Sarrazin, Scarselli, Shailesh Date, Sharookh B. Kapadia, Tommy K. Cheung, Trowbridge, Tsukiyama-Kohara, Utachee, Wang, Wei, Yi, Yi, Zhang, Zhang, Zhong   +81 more
core   +1 more source

Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts

Translational Oncology, 2017
Chemokines are small soluble molecules that play critical roles in wound healing, infection, and cancer progression. In particular, overexpression of the C-C motif chemokine ligand 2 (CCL2) in multiple cancer types correlates with poor patient prognosis.
Min Yao, Curtis Smart, Qingting Hu, Nikki Cheng   +3 more
doaj   +1 more source

Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster.

PLoS ONE, 2023
Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-responders depends on therapeutic antibodies or small-molecule drugs in cases of severe disease.
Stine Sofie Frank Lende, Nanna Møller Barnkob, Randi Westh Hansen, Harsh Bansia, Mike Vestergaard, Frederik Holm Rothemejer, Anne Worsaae, Deijona Brown, Maria Lange Pedersen, Anna Halling Folkmar Rahimic, Anna Karina Juhl, Torben Gjetting, Lars Østergaard, Amédée Des Georges, Laurent-Michel Vuillard, Mariane Høgsbjerg Schleimann, Klaus Koefoed, Martin Tolstrup   +17 more
doaj   +1 more source

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

medRxiv, 2020
Background. COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging. Methods.
Xiaoli Wang, Xianghua Guo, Qianqian Xin, Yang Pan, Yalin Hu, Jing Li, Y. Chu, Yingmei Feng, Quanyi Wang   +8 more
semanticscholar   +1 more source

Broadly neutralizing antibodies target a haemagglutinin anchor epitope

Nature, 2021
Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus have the potential to provide near universal protection against influenza virus infection1.
Jenna J. Guthmiller, Julianna Han, Henry A. Utset, Lei Li, L. Lan, Carole J Henry, Christopher T. Stamper, Meagan McMahon, George O’Dell, M. Fernández-Quintero, Alec W. Freyn, F. Amanat, O. Stovicek, Lauren E. Gentles, Sara T. Richey, A. T. de la Peña, Victoria C. Rosado, H. Dugan, Nai-Ying Zheng, Micah E. Tepora, Dalia J. Bitar, Siriruk Changrob, Shirin Strohmeier, Min Huang, A. García-Sastre, K. Liedl, J. Bloom, Raffael Nachbagauer, P. Palese, F. Krammer, Lynda Coughlan, A. Ward, P. Wilson   +32 more
semanticscholar   +1 more source

Feline Immunodeficiency Virus (FIV) Neutralization: A Review

Viruses, 2011
One of the major obstacles that must be overcome in the design of effective lentiviral vaccines is the ability of lentiviruses to evolve in order to escape from neutralizing antibodies.
Margaret J. Hosie, Daniela Pajek, Brian J. Willett, Ayman Samman   +3 more
doaj   +1 more source

Antibody neutralization of HIV-1

Immunology Today, 1996
Neutralizing antibodies are a major component of host defense against viruses, and appear to be particularly important in limiting the spread of cell-free virus. Results from vaccine trials in animal models suggest that these antibodies may contribute to protection against human immunodeficiency virus (HIV) infection.
Poignard, P, Klasse, P, Sattentau, Q
openaire   +2 more sources

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.

Annual Review of Medicine, 2021
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Dapeng Li, G. Sempowski, K. Saunders, P. Acharya, B. Haynes   +4 more
semanticscholar   +1 more source

TIV vaccination modulates host responses to influenza virus infection that correlate with protection against bacterial superinfection [PDF]

, 2019
Background: Influenza virus infection predisposes to secondary bacterial pneumonia. Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less effective if the induction of neutralizing antibodies is low and/or the
Choi, Angela, Christopoulou, Ioanna, García-Sastre, Adolfo, Saelens, Xavier, Schotsaert, Michael   +4 more
core   +2 more sources

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source